Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 8/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.43 |
| ▸ | CASR | P41180 | 8/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27530769 | 1.00 | ADRB2 (0.47) | ADRB2ADRB1ADRB3CASR | |
| SCHEMBL4502321 | 0.82 | KCNH2 (0.34) | ADRB2ADRB1 | |
| SCHEMBL4502328 | 0.82 | KCNH2 (0.34) | ADRB2ADRB1 | |
| SCHEMBL4560173 | 0.82 | KCNH2 (0.34) | ADRB2ADRB1 | |
| SCHEMBL4502326 | 0.82 | KCNH2 (0.34) | ADRB2ADRB1 | |
| SCHEMBL615848 | 0.81 | ADRB1 (0.43) | ADRB2ADRB1ADRB3CASR | |
| SCHEMBL27717030 | 0.81 | ADRB1 (0.43) | ADRB2ADRB1ADRB3CASR | |
| SCHEMBL615826 | 0.81 | ADRB1 (0.43) | ADRB2ADRB1ADRB3CASR | |
| SCHEMBL3838321 | 0.80 | ACACB (0.34) | — | |
| SCHEMBL13976846 | 0.80 | ACACB (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150065490-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2015-03-05 | — | — | US | disclosed |
| EP-1529038-B1 | BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY | NOVARTIS AG (CH) | 2009-10-07 | — | — | EP | disclosed |
| US-20070249586-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | CUENOUD BERNARD | 2007-10-25 | — | — | US | disclosed |
| CN-1301980-C | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | NOVARTIS AG (CH) | 2007-02-28 | — | — | CN | disclosed |
| CN-1917875-A | Combination of benzothiazol-2-one beta2 adrenoceptor agonists and corticosteroids for the treatment of respiratory diseases | NOVARTIS AG (CH) | 2007-02-21 | — | — | CN | disclosed |
| US-20060106075-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | NOVARTIS AG (CH) | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249586-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | ADRB2, ADRB1, ADRA2C | ADRB2 1/4885ADRB1 2/4885ADRB3 5/4885 |
| US-20060106075-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | ADRB2, ADRB1, ADRA2C | ADRB2 1/4885ADRB1 2/4885ADRB3 5/4885 |
| US-20150065490-A1 | ORGANIC COMPOUNDS | ADRB2, ADRA2C, ADRB1 | ADRB2 1/4885ADRB1 3/4885ADRB3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.